About Clinic

IVF CUBE – Clinic for Assisted Reproduction is dedicated to the issue of infertility diagnosis and the treatment of fertility disorders. We provide a broad range of treatment methods and additional techniques that increase not only the treatment success rates, but also the comfort of our patients.

Home->Clinic->About Clinic

 

Established in 2011, our clinic is based on tradition, experience and continual education in the field of reproductive medicine. Our specialists have gained experience at the most reputable centres specialized in reproductive medicine, both in the Czech Republic and abroad. Thanks to our professional expertise, we have been able to build a modern centre which has precise technical equipment, sophisticated processes and effectively trained personnel. We hope that these solid foundations enable us to provide our clients not only with advanced care, but also with comfort and safety in a friendly environment.

We understand that going through the process of fertility treatment may be challenging and stressful. That is why we provide support for our patients throughout the entire process. Our treatment coordinators are happy to answer any question and discuss each and every doubt. To increase the comfort of our foreign patients, we make use of partner clinics and doctors abroad that provide our patients with satellite services before, during and after therapy.

We regularly participate in international clinical surveys and studies which contributes to the overall development of the field of assisted reproduction. We are happy to enable our patients to closely monitor the progress of their therapy, to get a deeper understanding of the laboratory processes and fully participate in every step and decision made throughout the duration of their journey to the desired goal. We conceived the clinic's equipment at IVF CUBE in such a way that every moment of this journey can be visually monitored – starting with the egg collection, their quality consideration, up to the cultivation of the embryo stage. Based on this strategy and vision, we endeavor to convey to our patients as much information as we can in regards to the infertility treatment, so that we can help ease the decision-making process, and contribute to the patients' peace of mind.

We believe that we can guide you towards a new life.

See the inside of our clinic and discover who is on our team.

Accreditation

SUKL license for IVF CUBE

The State Institute for Drug Control (SUKL) in the Czech Republic control administrates surveillance over donation, purchase, examination, fabrication, storage and distribution of human tissues and cells aims at guarantee of their quality and safety. Part of this activity is issuance of certificate authorising the activity of tissue establishment, procurement site or diagnostic laboratories, control conduct, severe adverse events monitoring or suspect thereof, in cases of doubt whether tissues and cells governed by Act No. 296/2008 Coll., on provision of quality and safety of human tissues and cells designated for use in humans and changes to some related Acts (Act on human tissues and cells), as amended, are concerned.

These Acts came into existence as the Czech implementation of numerous EU directives. This strict regulation assures the highest quality in the field of reproductive medicine for each member of European Union.

The particular directives are:

  • Commission Directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells.
  • Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells.
  • Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells.
  • Corrigendum to Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004.

You can find the SUKL license to operate for IVF CUBE here: SUKL License to Operate

Authorization to operate

The bacic license needed to run the IVF CUBE clinic is an authorization to operate a private healthcare facility. This authorization is issued by the appropriate regional authority by place of operation of the private healthcare facility, or other government bodies defined by law.

You can find the authorization to operate a private healthcare facility - IVF CUBE here: Authorization to Operate for IVF CUBE

IVF CUBE laboratory accreditation

The IVF CUBE laboratory fulfilled all conditions for obtaining accreditation by the currently highest standards CSN EN ISO 15189:2013: Medical laboratories - Particular requirements for quality and competence of laboratory processes related to human gametes and embryos.

IVF CUBE has been entitled to use the assigned acreditation mark:

You can find the Certificate of Accreditation here: Certificate of Accreditation IVF CUBE CSN EN ISO 15189:2007

Reference to the Certificate on the site of Czech Accreditation Institute: http://www.cia.cz/en/Subjekt.aspx?ID=11149

Publications

Publications

  • Arce JC, Andersen AN, Fernández-Sánchez M, Visnova H, Bosch E, García-Velasco JA, Barri P, de Sutter P, Klein BM, Fauser BC. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2014 Dec; 102(6):1633-40.e5. doi: 10.1016/j.fertnstert.2014.08.013. Epub 2014 Sep 23. Online <http://www.sciencedirect.com/science/article/pii/S001502821402072X>.
  • Visnova H, Huttelova R, Budka S, Bahnikova M. Strategy to prevent the failure of GnRH agonist (GnRH-a) to trigger final oocyte maturation in patients with high risk of OHSS stimulated with antagonist protocol. In Abstracts of the 30th Annual Meeting of the European Society of Human Reproduction and Embryology. Munich 29 June to 2 July 2014. Poster topic: Reproductive endocrinology. Poster number: P-549. Online <https://www.eshre.eu/~/media/sitecore-files/Annual-meeting/Munich/ESHRE_2014_ABSTRACT-BOOK_opt.pdf>. 
  • Arce JC, Nyboe Andersen A, Fernández-Sánchez M, Visnova H, Bosch E, García-Velasco JA, Barri P. de Sutter P, Klein BM, Fauser CTM. Relation between dose of FE 999049, a recombinant FSH derived from a human cell-line, used for controlled ovarian stimulation and number of oocytes, embryos and blastocysts. In Abstracts of the 30th Annual Meeting of the European Society of Human Reproduction and Embryology. Munich 29 June to 2 July 2014. Poster topic: Reproductive endocrinology. Poster number: P-492. Online <https://www.eshre.eu/~/media/sitecore-files/Annual-meeting/Munich/ESHRE_2014_ABSTRACT-BOOK_opt.pdf>.
  • Brezinova J, Visnova H, Huttelova R. Myths about Fertility and ART success rates – Results of the Survey. In Abstracts of the 30th Annual Meeting of the European Society of Human Reproduction and Embryology. Munich 29 June to 2 July 2014. Poster topic: Psychology and counselling. Poster number: P-338. Online <https://www.eshre.eu/~/media/sitecore-files/Annual-meeting/Munich/ESHRE_2014_ABSTRACT-BOOK_opt.pdf>.
  • Visnova H, Pierson RA, Mrazek M, García-Velasco, Blockeel, C, Arce JC. Effects of barusiban, a selective oxytocin antagonist, on uterine contractility in the luteal phase after controlled ovarian stimulation. In Sbornik abstract, 22. Sympozium asistovane reprodukce. Brno 13 to 14 November 2012. Online <http://www.meritis.cz/dokumenty/kongresy/43/abstrakt2012.pdf>.
  • Visnova H, Pierson RA, Mrazek M, García-Velasco, Blockeel, C, Arce JC. Effects of barusiban, a selective oxytocin antagonist, on uterine contractility in the luteal phase after controlled ovarian stimulation. Fertility and Sterility, Sep 1 2012, Volume 98, Issue 3, S183.
  • Derbyshire E. Nutrition in the Childbearing Years. I. Title. Chichester, UK: Wiley-Blackwell, 2011. 336p. ISBN: 978-1-4443-4477-6.
  • Crha I, Hruba D, Ventruba P, Fiala J, Totusek J, Visnova H. Ascorbic acid and infertility treatment. Central European Jurnal of Public Health, 2003, Volume 11, Issue 2, 63-7.
  • Andersen, AN, Fernandez-Sanchez, M, Bosch, E, Visnova, H, Barri, P, Garcia-Velasco, JA, De Sutter, P, Fauser, BJCM, Arce, JC. A randomised, assessor-blind, dose-response trial in patients undergoing COS for IVF/ICSI with a  novel recombinant FSH (FE 999049) derived from a human cell line. Human Reproduction, Jun 2013, Volume 28, Issue 3, S351-352.
  • Visnova H, Pierson RA, Mrazek M, García-Velasco, Blockeel, C, Arce JC. Effects of barusiban, a selective oxytocin antagonist, on uterine contractility in the luteal phase after controlled ovarian stimulation. In Sbornik abstract, 22. Sympozium asistovane reprodukce. Brno 13 to 14 November 2012. Online < http://www.meritis.cz/dokumenty/kongresy/43/abstrakt2012.pdf>.
  • Visnova H, Pierson RA, Mrazek M, García-Velasco, Blockeel, C, Arce JC. Effects of barusiban, a selective oxytocin antagonist, on uterine contractility in the luteal phase after controlled ovarian stimulation. Fertility and Sterility, Sep 1 2012, Volume 98, Issue 3, S183.
  • Huttelova R, Kleibl Z, Kleiblova P, Visnova H, Uher P. PCR-PGD pro hereditární nádorové syndromy – first report pro BRCA1/2. Czech and Slovak Conference for Reproductive Gyneacology. Brno, 9. – 10. November, 2010. Published in Prakticka gynekologie, 2010, 13 (suppl. 1): 13-14.
  • Huttelova R, Visnova H, Uher P. Oocyte vitrification in case of semen deficiency in IVF treatment. Czech and Slovak Conference for Reproductive Gyneacology. Brno, 9. – 10. November, 2010. Published in Prakticka gynekologie, 2010, 13 (suppl. 1): 13-14.
  • Derbyshire E. Nutrition in the Childbearing Years. I. Title. Chichester, UK: Wiley-Blackwell, 2011. 336p. ISBN: 978-1-4443-4477-6.
  • Crha I, Hruba D, Ventruba P, Fiala J, Totusek J, Visnova H. Ascorbic acid and infertility treatment. Central European Jurnal of Public Health, 2003, Volume 11, Issue 2, 63-7.
  • Uher P, Baborova P, Visnova H, Losan P, Martinek P. Our experience with Preimplantation Genetic Diagnosis. Symposium of Assisted Reproduction. Brno, November 21. – 22., 2007. Published in Prakticka gynekologie, 2007; 11 (suppl. 6): p-273.
  • Chovanec J, Visnova H, Sik S, Petrenko M, Unzeitig V. The influence of the breast cancer chemotherapy to the menstrual cycle. 11th International Meeting of Gynaecological Oncology. May 08-12, 1999, Budapest.
  • Unzeitig V, Siegelova V, Paseka J, Visnova H. Contraception and STD prevention. In International Congress, Symposium and Seminar Series of the 5th Congress of the European Society of Contraception. 1998, Prague.
  • Zakova J, Ventruba P, Crha I,Visnova H. Effectiveness of frozen-thawed embryo transfer in the years 1996 and 1997. Human Reproduction, Jun 1998, Volume 13, Special Issue, S297-297.

 

Clinical trials

Title

A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day 3 and Day 5 fresh embryo transfer cycles.

EudraCT No

2016-004266-25

Sponsor

ObsEva S.A., Switzerland

Sponsor Protocol No

16-OBE001-005

 

Title

A Randomized, Open-label, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy of MENOPUR Versus Recombinant FSH in Controlled Ovarian Stimulation Following a GnRH Antagonist Protocol and Single Embryo Transfer

EudraCT No

2008-006775-67

Sponsor

Ferring Pharmaceuticals A/S, Denmark

Sponsor Protocol No

FE 999906 CS08

 

Title

A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Multi-centre Trial in Oocyte Donors Assessing the Effects of Barusiban, a Selective Oxytocin Antagonist, on Uterine Contractions on the Day of Embryo Transfer

EudraCT No

2009-012323-29

Sponsor

Ferring Pharmaceuticals A/S, Denmark

Sponsor Protocol No

FE200440CS11

 

Title

A randomised, controlled, assessor-blind, parallel groups, multinational, multicentre trial assessing the dose-response relationship of FE 999049 in controlled ovarian stimulation in women undergoing an assisted reproductive technology programme.

EudraCT No

2011-000633-36

Sponsor

Ferring Pharmaceuticals A/S, Denmark

Sponsor Protocol No

000009

 

Title

A randomised, placebo-controlled, double-blind, parallel groups, multinational, multicentre trial assessing the effect of barusiban administered subcutaneously on the day of transfer on implantation and pregnancy rates in IVF/ICSI patients.

EudraCT No

2012-001622-10

Sponsor

Ferring Pharmaceuticals A/S, Denmark

Sponsor Protocol No

000048

 

Title

A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Comparing the Efficacy and Safety of FE 999049 With Follitropin Alfa (GONAL-F) in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme

EudraCT No

2013-001669-17

Sponsor

Ferring Pharmaceuticals A/S, Denmark

Sponsor Protocol No

000004

 

Title

A Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Evaluating the Immunogenicity of FE 999049 in Repeated Cycles of Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme

EudraCT No

2013-001616-30

Sponsor

Ferring Pharmaceuticals A/S, Denmark

Sponsor Protocol No

000071

 

Title

A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris® (follitropin alfa and lutropin alfa) and GONAL-f® (follitropin alfa) for multifollicular development as part of an assisted reproductive technology treatment cycle in poor ovarian responders, as defined by the European Society of Human Reproduction and Embryology criteria

EudraCT No

2013-003817-16

Sponsor

Merck KGaA

Sponsor Protocol No

EMR200061-005

 

Title

A Phase 2, Double-blind, Dose-finding, Placebo-controlled Study to Assess the Safety and Efficacy of a Single Oral Administration of OBE001 to Improve Embryo Implantation Following IVF or ICSI

EudraCT No

2014-002254-40

Sponsor

ObsEva SA

Sponsor Protocol No

14-OBE001-013

 

 

To book a consultation or to ask a question, feel free to
Egg Donation